Company intelligence / Profile preview

SCIENION

Ownership: Private
Employees: ~111
Development stage: Commercial

Overview

SCIENION provides commercial-stage precision dispensing platforms for ultra-low volume liquid handling and microarray manufacturing. Their technologies are widely adopted in life sciences for multiplex assays and single-cell applications. No clinical results as they do not develop therapeutics.

Therapeutic areas: Other
Modalities: Device (precision dispensing systems)Microarray technology platformSingle cell isolation and dispensing technologyNot directly therapeutic modalities; enables work with oligonucleotides, proteins, antibodies, glycans, cells
Industry: Non-Drug Biotech

Partnerships

Participates in national/international research projects with academic and industrial partners; joint “CellSpace” laboratory with Biopredic International at Hospital Paul-BrousseI near Paris.

Beyond the preview

Go deeper on SCIENION.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCIENION.

Explore the full profile